News

Biennial mammography keeps women safe and saves billions of dollars

View on the News

Make screening costs part of the conversation

We applaud [Dr.] O’Donoghue and [her] colleagues for meticulously assessing the total cost of breast cancer screening in the United States. Although there is often cause to be skeptical about simulation models because results are based on numerous assumptions, we find the article by O’Donoghue and colleagues to be reasonable and conservative.

Integrating cost into the cancer screening conversation is a challenge. Providers and patients are not only shielded from cost information, but some may raise concerns that the mere mention of costs is a step down the road to rationing. However, both advocates and skeptics should know the costs associated with different breast-cancer screening strategies, particularly when there is so much debate about which approach is most effective.

Costs, including out-of-pocket costs, should be part of the conversation because women with high-deductible health plans may find themselves facing a hefty bill for adjunctive imaging tests and procedures. At the societal level, costs should be integrated into our national dialogue about screening. It is unsustainable to remain ignorant of the costs associated with any health intervention, even breast-cancer screening.

The approximate $8 billion difference among breast-cancer screening strategies is roughly twice as large as the entire annual budget of the National Cancer Institute.

Dr. Joann Elmore and Dr. Cary Gross made the above comments in an editorial accompanying the study (Ann. Intern. Med. 2014 Feb. 3;160:203-4). Dr. Elmore is a professor of medicine at the University of Washington in Seattle. Dr. Gross is a professor of medicine at Yale University in New Haven, Conn., and director of the school’s Cancer Outcomes Public Policy and Effectiveness Research Center. Dr. Gross is a paid Fair Health Inc. board member and disclosed grants from Medtronic and 21st Century Oncology.


 

FROM THE ANNALS OF INTERNAL MEDICINE

Following United States Preventive Services Task Force mammography screening guidelines would save about $4.4 billion annually, without sacrificing quality of care, according to a study published online Feb. 3 in the Annals of Internal Medicine.

Taking the costs of mammography, computer-aided detection, recalls, biopsies, and other variables into account, the investigators estimated that it would have cost $3.5 billion to screen 85% of women in 2010 who met the USPSTF criteria: Screen women aged 50-74 years every other year, plus high-risk women aged 40-49 years and women aged 75-85 years with few comorbidities biennially (Ann. Intern. Med. 2014 Feb. 3;160:145-53 [doi:10.7326/M13-1217]).

© Bill Branson/National Cancer Institute

Taking the costs of mammography, computer-aided detection, recalls, biopsies, and other variables into account, the investigators estimated that it would have cost $3.5 billion to screen 85% of women in 2010 who met the USPSTF criteria.

Instead, $7.8 billion was actually spent in 2010 to screen just 70% of women using the mélange of screening practices in place today in the United States, a byproduct of the country’s uncertainty about the right way to proceed, the researchers noted.

Meanwhile, following the advice of the American Cancer Society and other groups for annual screenings of women aged 40-84 years would have cost $10.1 billion if 85% had come into the clinic. Screening 85% of women aged 50-69 years biennially – in keeping with the European approach – would have cost $2.6 billion.

Previous studies have found fewer false-positives and recalls with biennial screening, and no significant increase in late-stage cancer detections, said Dr. Cristina O’Donoghue of the University of Illinois at Chicago and her associates.

"Following mammography screening guidelines, such as those from the USPSTF, [which] optimize frequency on the basis of best-available evidence will ... improve screening and save billions of dollars," money that’s better spent on expanding mammography access and increasing risk-based screening, breast-cancer prevention, and mammography reading by experts less likely to make mistakes, among other things, the researchers said.

Dr. Cristina O’Donoghue

Even so, "in the United States, there has been resistance to reducing frequency or modifying the age-range for mammography. Those who advocate annual screening should justify the increased costs of nearly $7 billion per year, compared with biennial policies," they said.

The project was a modeling exercise to price out various approaches to breast cancer screening using Medicare reimbursement rates; census figures; Breast Cancer Surveillance Consortium records; and other data sources. The researchers stated that they thought the cost information would help doctors, women, and policy makers find the right approach, especially as the Affordable Care Act improves mammography access and increases screening rates.

The U.S. task force’s biennial approach "is in line with our national goals of advancing health care delivery while improving cost-efficiency," the researchers said.

They concluded that screening frequency is the main driver of costs in mammography, followed by the percentage of women screened, cost per screen, percentage of women screened with digital mammography, and percentage of mammography recalls.

The researchers had no financial conflicts to disclose. The study was funded by the University of California and the Safeway Foundation.

aotto@frontlinemedcom.com

Recommended Reading

Veliparib-carboplatin combo is first 'graduate' of I-SPY2 trial
MDedge Hematology and Oncology
Meeting attendees identify top studies presented at SABCS
MDedge Hematology and Oncology
'Vogl, New York' offers San Antonio perspectives
MDedge Hematology and Oncology
Breast MRI screening finds undetected cancers in 11 per 1,000 average-risk women
MDedge Hematology and Oncology
Exercise protects black women against ER-negative breast cancer
MDedge Hematology and Oncology
Primary care screening advised to select women for BRCA counseling
MDedge Hematology and Oncology
No overall benefit seen with bisphosphonate treatment in chemoresistant breast cancer
MDedge Hematology and Oncology
Survival no better after primary tumor removal in metastatic breast cancer
MDedge Hematology and Oncology
Will 100% coverage spur more use of breast cancer chemopreventives?
MDedge Hematology and Oncology
Obesity and Gynecologic Cancer
MDedge Hematology and Oncology